Decision making in feline oncology
This course is available online. Please see below for more details on how to attend this course via the Internet.
About this course
Cancer is a major disease of cats in terms of health and welfare with an estimated incidence of around 1 in 5 cats developing the disease during their lifetime. Cats present specific challenges to oncologists in terms of diagnosis and management of cancers, not least in terms of their ability to tolerate specific drug regimes. For many years feline cancer medicine was dominated by virally induced Lymphoma. While Lymphoma is still a major problem in cats, the increase in vaccination has reduced the incidence of this disease and allowed other tumours to become prominent players, particularly diseases such as Squamous Cell Carcinoma, Mast Cell Disease and Injection Site Sarcomas.
This webinar aims to look at feline oncology in more detail with regard to approach and diagnosis, treatment and prognosis. More specifically the webinar we will explore:
- The special considerations in cats with regards diagnosis and treatment.
- Special considerations for treatment modalities in cats
- Cancer-related syndromes in cats and their management
- The manifestation of treatment-related problems in cats and the specific management of side-effects.
- Particular emphasis will be placed upon the special considerations in cats with regards drug metabolism, nutritional support during therapy and prognosis of individual diseases.
We will relate these considerations to the current approach and treatment regimes for the most common types of cancer in cats. These will include:
- Feline GI Lymphoma: Including challenges in making a diagnosis and chronic drug management.
- Mast cell diseases: Including both cutaneous and visceral forms and the use of surgery and chemotherapy.
- Injection site sarcomas: Including the challenges to diagnosis, the role of both surgery and radiation and decision making in terms of how we vaccinate cats.
- Mammary Tumours: Including the use of adjunctive chemotherapy.
In the final part of the lecture we will look at horizon scanning in terms of the potential for new diagnostic tests and the development of new drugs and biological approaches to feline cancer.
David Argyle graduated from the University of Glasgow. After a period in practice he returned to Glasgow to complete a PhD in Oncology/Immunology. He was senior lecturer in clinical oncology at Glasgow until 2002 when he became head of veterinary oncology at the University of Wisconsin-Madison, USA. In 2005 he returned to Edinburgh University to the William Dick Chair of Veterinary Clinical Studies. In 2009 he became the dean for postgraduate research and international for both medicine and veterinary medicine. In 2011 he was appointed as Head of School and Dean for the Royal (Dick) School of Veterinary Studies. He in an RCVS/European specialist in Veterinary Oncology, Diplomat of the European College of Internal Medicine in Oncology and co-scientific editor of the Journal of Veterinary and Comparative Oncology. His major research interests are cancer and stem cell biology.